Trial Profile
Phase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Pituitary adenoma
- Focus Registrational; Therapeutic Use
- Sponsors Teijin Pharma
- 01 Dec 2017 New trial record